A61K 38/385
Serum albumin
Official title: {Serum albumin}
A61K38/385 (Serum albumin) appears on 235 US grants and 472 published applications in this corpus.
Search patents in A61K- Granted patents
- 235
- Published applications
- 472
- Assignees
- 244
- Inventors
- 826
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 2 |
| 2003 | 1 | 2 |
| 2004 | 0 | 2 |
| 2005 | 1 | 2 |
| 2006 | 1 | 3 |
| 2007 | 0 | 4 |
| 2008 | 0 | 6 |
| 2009 | 2 | 10 |
| 2010 | 2 | 6 |
| 2011 | 3 | 9 |
| 2012 | 7 | 13 |
| 2013 | 7 | 23 |
| 2014 | 14 | 27 |
| 2015 | 12 | 36 |
| 2016 | 15 | 39 |
| 2017 | 18 | 33 |
| 2018 | 20 | 26 |
| 2019 | 27 | 42 |
| 2020 | 19 | 26 |
| 2021 | 22 | 33 |
| 2022 | 17 | 35 |
| 2023 | 14 | 29 |
| 2024 | 11 | 20 |
| 2025 | 9 | 25 |
| 2026 | 11 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Composition comprising albumin for use in the treatment of amyotrophic lateral sclerosis (ALS) by plasma exchange15 Sep 2026US 12,734,220 B2Grifols Worldwide Operations Limited
- Delivery of nucleic acids, proteins and small molecules in vitreous vesicular bodies18 Aug 2026US 12,708,647 B2Cornell University
- Blood plasma fractions as a treatment for aging-associated cognitive disorders4 Aug 2026US 12,697,373 B2Alkahest, Inc.
- Albumin-proaerolysin prodrugs28 Jul 2026US 12,691,158 B2The Johns Hopkins University
- Aqueous pharmaceutical composition containing fusion protein of serum albumin and growth hormone21 Jul 2026US 12,685,762 B2JCR Pharmaceuticals Co., Ltd.
- Particles and suspensions comprising hyaluronan degrading agents and methods of use thereof1 Oct 2026US 2026/0295021 A1Halozyme Hypercon, Inc.
- Blood Plasma Fractions as a Treatment for Aging-Associated Cognitive Disorders17 Sep 2026US 2026/0273026 A1Alkahest, Inc.
- Compositions of Blood Plasma Fractions and Blood Plasma Subfractions and Their Use in Treatment of Disease10 Sep 2026US 2026/0263512 A1Alkahest, Inc.
- Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndrome10 Sep 2026US 2026/0265388 A1Viela Bio, Inc.
- Methods for Improving Leptin Sensitivity for the Treatment of Obesity and Diabetes3 Sep 2026US 2026/0256888 A1University of Massachusetts
Most cited
By later US patents
- Protein formulations and methods of making same92US 8,883,146 B2AbbVie Inc. · 2014
- Anti-TNF antibody formulations81US 9,085,619 B2AbbVie Biotechnology Ltd. · 2015
- Posterior segment drug delivery78US 8,399,006 B2ForSight Vision4, Inc. · 2013
- Delivery of nucleotides into organisms by electroporation74US 5,749,847 AMassachusetts Institute of Technology · 1998
- Posterior segment drug delivery68US 8,277,830 B2ForSight Vision4, Inc. · 2012